Literature DB >> 18221027

Inhibitors for metastasis development.

Kerstin Lang1, Theodore L Drell, Kurt S Zaenker, Frank Entschladen.   

Abstract

A leading cause of death, cancer remains the bane of modern society and one of the most challenging research fields. Cancer is initially a localized disease that can be often treated well at a very early stage. However the vast majority of cancer deaths result from a pernicious progression of the disease, the development of distant metastases. It must therefore be a pressing research goal to focus on the pharmacological prevention of metastasis development. This review summarizes the current understanding of the cellular and molecular mechanisms of metastasis development, and suggests possible approaches for its inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18221027     DOI: 10.2174/157489206775246511

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  4 in total

1.  Significance of PELP1 in ER-negative breast cancer metastasis.

Authors:  Sudipa Roy; Dimple Chakravarty; Valerie Cortez; Keya De Mukhopadhyay; Abhik Bandyopadhyay; Jung-Mo Ahn; Ganesh V Raj; Rajeshwar R Tekmal; LuZhe Sun; Ratna K Vadlamudi
Journal:  Mol Cancer Res       Date:  2011-11-15       Impact factor: 5.852

2.  Quantitative glycoproteomic analysis of optimal cutting temperature-embedded frozen tissues identifying glycoproteins associated with aggressive prostate cancer.

Authors:  Yuan Tian; G Steven Bova; Hui Zhang
Journal:  Anal Chem       Date:  2011-08-18       Impact factor: 6.986

3.  GABA receptor expression in benign and malignant thyroid tumors.

Authors:  Stephen S Roberts; Maria Cecilia Mendonça-Torres; Kirk Jensen; Gary L Francis; Vasyl Vasko
Journal:  Pathol Oncol Res       Date:  2009-04-19       Impact factor: 3.201

4.  Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.

Authors:  Desmond G Powe; Melanie J Voss; Kurt S Zänker; Hany O Habashy; Andrew R Green; Ian O Ellis; Frank Entschladen
Journal:  Oncotarget       Date:  2010-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.